南京药石科技股份有限公司 2024年度董事会工作报告 2024 年，公司董事会严格按照《公司法》《证券法》等法律法规以及《公司 章程》等规章制度的规定，充分发挥"定战略、作决策、防风险"作用，以保障 全体股东权益为目标，恪尽职守、积极有效的行使职权，不断推动公司治理水平 的提高和公司各项业务的健康发展。现将公司董事会 2024 年工作情况汇报如下： 一、 2024 年公司经营情况概述 2024 年，面对复杂多变的外部环境，公司坚持以市场为导向，以客户为中 心，持续提升交付能力与服务质量，推动技术平台创新与应用转化，积极应对全 球生物医药投融资规模收缩、产业链需求端结构性调整、市场竞争激烈等不利因 素。本报告期，公司营业收入 16.89 亿元，同比下降 2.12%。第四季度，随着行 业需求的初步改善及商业化项目订单交付，本季度营业收入 5.61 亿元，同比增 长 29.28%；叠加公司前期一系列降本控费、提质增效措施继续有效实施，2024 年 公司实现归属于上市公司股东的净利润 2.20 亿元，同比增长 11.24%；扣除非经 常性损益的净利润 1.73 亿元，同比下降 1.66%。报告期内，公司加大客户信用 ...

2024 年度监事会工作报告 2024 年，南京药石科技股份有限公司（以下简称"公司"）监事会全体成员 严格按照《公司法》《证券法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》《监事会议事规则》等相关要 求，本着恪尽职守、勤勉尽责的工作态度，独立行使职权，积极有效地开展工作， 维护了公司及股东的合法权益。监事会对公司依法运作情况、财务状况、重大事 项决策、募集资金使用以及董事、高级管理人员履职情况等进行监督，确保公司 规范运作。现将监事会本年度的主要工作报告如下： 一、 2024 年度监事会日常工作及会议召开情况 目前公司共有监事 3 名，其中职工代表监事 1 名。监事会的人数及人员构成 符合法律、法规的要求。监事会对报告期内的监督事项无异议。 南京药石科技股份有限公司 | 届次 | | 时间 | | | 审议事项 | | --- | --- | --- | --- | --- | --- | | 第三届监事会第十八次会议 | 2024 年 4 | 月 | 23 | 日 | 1、《关于公司<2023 年年度报告及摘要>的议案》 | | | | | | | 2、《关于 ...

南京药石科技股份有限公司 2024年度内部控制自我评价报告 南京药石科技股份有限公司全体股东： 南京药石科技股份有限公司（以下简称"公司"）董事会根据《企业内部 控制基本规范》《企业内部控制应用指引》和《深圳证券交易所创业板股票上 市规则》《深圳证券交易所创业板上市公司规范运作指引》等文件要求（以下 简称"企业内部控制规范体系"），结合本公司内部控制制度和评价办法，在 内部控制日常监督和专项监督的基础上，我们对公司截止至2024年12月31日 （内部控制评价报告基准日）的内部控制有效性进行评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价 其有效性，并如实披露内部控制评价报告是公司董事会的责任。管理层负责组 织、领导企业内部控制的日常运行。公司董事会及董事、高级管理人员保证本报告 内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确 性和完整性承担法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告 及相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控 制存在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由 ...

关于 2025 年度开展外汇衍生品交易业务的公告 | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-019 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、为有效规避和防范汇率大幅波动对南京药石科技股份有限公司（以下简 称"本公司"）经营造成的不利影响，降低外汇风险，增强本公司财务的稳健性， 在保证日常运营资金需求的情况下，本公司及子公司拟在 2025 年度与境内外商 业银行开展额度不超过 30,000 万美元或其他等值人民币的外汇套期保值业务， 交易品种包括远期结售汇、人民币和其他外汇的掉期业务、外汇买卖、外汇掉期、 外汇期权、利率互换、利率掉期、利率期权等产品或上述产品的组合。 2、本次开展外汇套期保值业务已经本公司第四届董事会第四次会议审议通 过，尚需提交本公司股东大会审议。 3、风险提示：公司将遵循谨慎、稳健的风险管理原则开展外汇衍生品交易 业务，不进行以投机为目的的外汇衍生品业务， ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-020 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于 2025 年度向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 公司向银行申请授信额度的基本情况 二、 公司 2025 年向银行申请授信审批权限授权情况 公司董事会授权董事长杨民民先生代表本公司在上述授信额度内（包括但不 限于授信、借款、抵押、融资等）处理公司及控股子公司向银行等金融机构申请 授信并为控股子公司提供担保相关的一切事务，由此产生的法律、经济责任全部 由公司及控股子公司承担。 本议案尚需提交股东大会审议。 三、 备查文件 1、南京药石科技股份有限公司第四届董事会第四次会议决议 特此公告。 南京药石科技股份有限公司董事会 2025年4月25日 南京药石科技股份有限公司（以下简称"公司"、"药石科技"）于 2025 年 4 月 24 日召开的第四届董事会第四次会议审议通过了《关于公司 2025 年度向银 ...

南京药石科技股份有限公司 非经营性资金占用及其他 关联资金往来情况的专项 说明 苏公 W[2025]E1212 号 目 录 关于南京药石科技股份有限公司 非经营性资金占用及其他关联资金往来情况的专项说明 苏公W[2025]E1212号 1、非经营性资金占用及其他关联资金往来情况的专项说 明 …………………………………………………………………1 2、非经营性资金占用及其他关联资金往来情况汇总表 ………3 3、事务所营业执照复印件 4、事务所执业证书复印件 5、签字注册会计师资质证明复印件 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 中国．江苏．无锡 Wuxi．Jiangsu．China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 南京药石科技股份有限公司全体股东： 我们接受委托，按照中国注册会计师审计准则审计了南京药石科 ...

南 京 药 石 科 技 股 份 有 限 公 司 董 事 会 审 计 委 员 会 对 会 计 师 事 务 所 2 0 2 4 年度履职情况 评 估 及 履 行 监 督 职 责 情 况 的 报 告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》和《公司章程》等规定和 要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事 会审计委员会对会计师事务所 2024 年度履职评估的情况汇报如下： 一、 2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 公证天业会计师事务所（特殊普通合伙）（以下简称"公证天业"），创立于 1982 年，是全国首批经批准具有从事证券、期货相关业务资格及金融业务审计 资格的会计师事务所之一。2013 年 9 月 18 日，转制为特殊普通合伙企业。截止 2024 年 12 月 31 日，公证天业合伙人数量 59 人，注册会计师 349 人，签署过证 券服务业务审计报告的注册会计师人数 168 人。 （二）聘任会计师事 ...

Dividend Distribution - The company plans to distribute a cash dividend of 2.8 RMB per 10 shares to all shareholders, based on a total of 198,893,589 shares[3] - The company approved a cash dividend of 3.10 CNY per 10 shares, totaling 61,636,856.08 CNY (including tax) for the fiscal year 2023[199] - The total number of shares for the dividend distribution is based on 198,828,568 shares after excluding repurchased shares[199] - The dividend distribution was completed by the end of the reporting period, with the record date set for June 13, 2024, and the ex-dividend date on June 14, 2024[199] - The profit distribution plan aligns with the company's articles of association and dividend management policies[200] - The company has established a clear and transparent cash dividend policy that complies with relevant regulations[200] - There were no adjustments or changes to the cash dividend policy during the reporting period[200] - The company ensured that minority shareholders had opportunities to express their opinions and protect their legal rights[200] - The total number of shares for the dividend distribution plan was 198,893,589 shares[200] - The company maintained a consistent approach to profit distribution without any capital reserve transfers or stock dividends[200] Financial Performance - The company's operating revenue for 2024 was ¥1,688,619,647.07, a decrease of 2.12% compared to ¥1,725,203,986.49 in 2023[20] - The net profit attributable to shareholders for 2024 was ¥219,539,833.88, an increase of 11.24% from ¥197,360,947.76 in 2023[20] - The net cash flow from operating activities increased by 22.68% to ¥302,823,004.54 in 2024, compared to ¥246,839,976.80 in 2023[20] - The total assets at the end of 2024 were ¥4,935,272,666.40, a decrease of 3.31% from ¥5,104,032,178.39 at the end of 2023[20] - The company reported a basic earnings per share of ¥1.10 for 2024, up 11.11% from ¥0.99 in 2023[20] - The company's revenue for 2024 was 1.689 billion yuan, a year-on-year decrease of 2.12%[61] - In Q4 2024, revenue reached 561 million yuan, a year-on-year increase of 29.28%[61] - The net profit attributable to shareholders for 2024 was 220 million yuan, a year-on-year increase of 11.24%[61] - The number of active global customers increased by 12.32% to 775, with a total of 1,184 customers generating revenue[62] - Revenue from large multinational pharmaceutical companies was 464 million yuan, a year-on-year increase of 16.37%, accounting for 27.50% of total revenue[62] Market Trends and Industry Insights - The global healthcare industry saw a total investment of $58.013 billion in 2024, a 1% increase year-on-year, indicating a recovery trend[30] - The top 30 global pharmaceutical companies increased their R&D investment by 8.1% in 2024, driving demand for CXO preclinical and CMC services[30] - The domestic market in China experienced a financing amount of ¥42.117 billion in 2024, down approximately 38% year-on-year, but showed a quarter-on-quarter growth of 18% in the second half[30] - The company is leveraging self-built and acquisition strategies to expand production capacity overseas, particularly in Europe and Singapore[31] - China's small molecule CXO sector has established significant competitive advantages, including the largest active pharmaceutical ingredient production capacity and a compliance system aligned with international standards[31] - The global ADC drug pipeline has surpassed 380 projects, indicating a significant demand for core payload-linker technology[32] Research and Development - The company has a comprehensive drug research, development, and production solution platform for global partners[3] - The company is focusing on green transformation in pharmaceutical manufacturing, aligning with global sustainability trends[34] - The integration of AI and continuous manufacturing technologies is enhancing research and production efficiency, reducing costs[33] - The company is expanding its capabilities in the development of non-natural amino acids to meet the growing demand in peptide drug research[39] - The company offers a comprehensive CDMO service platform, covering the entire lifecycle from preclinical research to commercialization[37] - The company has established a diverse library of unique molecular building blocks, supporting various small molecule drug development needs[38] - The company has developed integrated collaborative service solutions that streamline the entire drug development process, enhancing project delivery efficiency and compliance[41] - The company has established a comprehensive management system covering quality management, EHS management, and supply chain management to support international business expansion[55] Operational Efficiency and Cost Management - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[9] - The company has achieved solvent recovery of nearly 3,400 tons in 2024, saving approximately 17 million in costs through technological innovations[86] - The company has implemented automated experimental platforms and smart algorithms to improve the automation and intelligence of the development process[48] - The company has established a chemical reaction engineering platform to support continuous flow process development and enhance overall technical capabilities[49] - The company has optimized existing chemical processes to enhance technological advancement and market competitiveness[53] Governance and Compliance - The company has a comprehensive governance structure in place, ensuring effective checks and balances among the board, management, and shareholders[149] - The company has maintained independence from its controlling shareholders in terms of assets, personnel, finance, and operations[152] - The company has a structured corporate governance framework, including a shareholders' meeting, board of directors, and supervisory board, ensuring independent management[157] - The company has a clear separation of labor contracts and management from the controlling shareholder, ensuring independence in human resources and compensation management[154] - The company has not faced any penalties from securities regulatory authorities for directors, supervisors, and senior management in the past three years[180] Strategic Initiatives and Future Outlook - The company plans to focus on "digital intelligence" and "low-carbon chemical technology" as strategic trends for its 2025 operational plan[130] - The company aims to enhance its customer value creation system by forming strategic customer service teams to ensure high-quality project delivery[131] - The company will increase its investment in technology innovation, particularly in low-carbon technology projects, to improve cost efficiency and operational effectiveness[133] - The company is committed to building a sustainable talent pipeline to support ongoing innovation and development[135] - The company’s future outlook remains positive, with expectations of continued revenue growth and market expansion initiatives[163] Human Resources and Employee Development - The total number of employees at the end of the reporting period is 2,400, with 1,325 in the parent company and 1,075 in major subsidiaries[195] - The company has 1,449 technical personnel, representing approximately 60.4% of the total workforce[195] - The company employs 115 individuals with a doctoral degree, 568 with a master's degree, and 1,031 with a bachelor's degree, indicating a highly educated workforce[195] - The company has implemented a dual career development path for employees, offering opportunities for both professional and managerial growth[196] - The training program for 2024 focuses on enhancing new employee integration, improving managerial practical abilities, and deepening cultural values[198] Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[3] - The report includes a detailed description of potential operational risks and corresponding mitigation measures[3] - The company is facing risks from global economic fluctuations and trade disputes, which may affect its overseas business operations[136] - The company recognizes the risk of intensified market competition and plans to strengthen its R&D capabilities to maintain its competitive edge[139] - The company has established risk control measures to avoid significant exchange rate fluctuations impacting its financials[114]

Revenue and Profit - The company's revenue for Q1 2025 was ¥455,018,107.75, representing a 20.55% increase compared to ¥377,460,431.51 in the same period last year[5] - Net profit attributable to shareholders decreased by 27.67% to ¥35,790,750.96 from ¥49,485,359.20 year-on-year[5] - Basic earnings per share fell by 28.00% to ¥0.18, compared to ¥0.25 in the same period last year[5] - Total operating revenue for the current period reached ¥455,018,107.75, an increase of 20.5% compared to ¥377,460,431.51 in the previous period[18] - Net profit for the current period was ¥35,790,750.96, a decrease of 27.7% from ¥49,485,359.20 in the previous period[19] - Earnings per share (EPS) for the current period was ¥0.18, down from ¥0.25 in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities surged by 356.06% to ¥252,341,548.08, up from ¥55,330,257.73 in the previous year[5] - Cash inflow from operating activities totaled ¥680,318,835.89, up from ¥464,763,229.08, indicating a year-over-year increase of 46.3%[21] - Cash outflow from operating activities was ¥427,977,287.81, compared to ¥409,432,971.35, reflecting a slight increase of 4.2%[21] - The net increase in cash and cash equivalents was ¥355,283,193.12, contrasting with a decrease of ¥68,173,430.97 in the previous period[22] - The ending balance of cash and cash equivalents stood at ¥645,483,817.56, up from ¥440,098,278.17, reflecting an increase of 46.6%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,914,980,393.45, a slight decrease of 0.41% from ¥4,935,272,666.40 at the end of the previous year[5] - Total liabilities decreased to ¥1,890,748,249.96 from ¥1,947,719,670.04[17] - Total equity attributable to shareholders increased to ¥3,024,232,143.49 from ¥2,987,552,996.36[17] Research and Development - The company's R&D expenses decreased by 37.53% to ¥21,559,149.46 from ¥34,513,051.40 year-on-year, reflecting ongoing adjustments in business layout[8] - Research and development expenses were ¥21,559,149.46, down from ¥34,513,051.40 in the previous period, indicating a focus on cost management[18] Operating Costs and Income - The company experienced a 46.54% rise in operating costs, totaling ¥316,982,758.01, attributed to revenue growth and market competition[8] - Total operating costs amounted to ¥412,531,258.48, up 26.8% from ¥325,204,409.51 in the prior period[18] - The company recorded a 310.18% increase in investment income to ¥4,356,576.46, compared to a loss of ¥2,072,743.28 in the previous year[8] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,741[10] - The top shareholder, Yang Minmin, holds 20.73% of the shares, amounting to 41,403,319 shares[10] - The company has a total of 0 preferred shareholders with voting rights restored[10] - The company has no changes in the number of preferred shareholders or restricted shares during the reporting period[12] Miscellaneous - The company reported a significant increase in contract liabilities by 74.31% to ¥97,821,118.13, indicating pre-received sales not yet recognized as revenue[8] - The company reported a significant increase in other revenue categories, with a 615.29% rise in miscellaneous income[13] - The company's inventory decreased to ¥780,902,805.72 from ¥840,165,143.36[15] - The total assets at the end of the reporting period are ¥2,713,972,014.09, slightly down from ¥2,716,938,169.24[15] - The company's first quarter report was not audited, as stated in the financial disclosures[23]

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-026 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于提请股东大会授权董事会以简易程序向 特定对象发行股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"或"药石科技"）根据《上 市公司证券发行注册管理办法》《深圳证券交易所上市公司证券发行上市审核规 则》《深圳证券交易所上市公司证券发行与承销业务实施细则》等相关规定，公 司董事会于2025年4月24日召开第四届董事会第四次会议，审议通过了《关于提 请股东大会授权董事会办理以简易程序向特定对象发行股票相关事宜的议案》， 同意董事会提请股东大会授权董事会以简易程序向特定对象发行融资总额不超 过人民币3亿元且不超过最近一年末净资产20%的股票，授权期限为2024年年度股 东大会审议通过之日起至2025年年度股东大会召开之日止。上述事项尚需公司 2024年年度股东大会审议通过。现将具体情况公告如下： 一、 ...